Nirsevimab-alip (Intramuscular Route)

• 2024

  Log in to bookmark this resource.

  Log in

---

Access Resources

• Job AidEN
• Ask aRCie About This Resource

About

This resource provides drug information for nirsevimab-alip (intramuscular route). It is to be administered to newborns and babies under 1 year old in their first RSV season. It is also given to children up to 24 months old who remain at risk of RSV disease in their second season. The medicine provides antibodies to protect against RSV infection. Proper use, prerecautions, and side effects are covered.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians; Public Health Professionals

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Breast Feeding; Infant; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Drug-Related Side Effects and Adverse Reactions; Antibodies, Monoclonal, Humanized

Institutions: Mayo Clinic; Merative

---

More like this

Pertussis in Children and Pregnant Women: Key Information for Healthcare Providers 2024 · Pediatric Pandemic Network (PPN) BD BACTEC Blood Culture Media Shortage 2024 · Pediatric Pandemic Network (PPN) Pediatric Pandemic Network Disaster Cycle 2025 · Pediatric Pandemic Network (PPN)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---